Research Topics
| Joep KillesteinSummaryAffiliation: VU University Medical Center Country: The Netherlands Publications
| Collaborators
|
Detail Information
Publications
[Medicinal cannabis for diseases of the nervous system: no convincing evidence of effectiveness]J Killestein
VU Medisch Centrum, Postbus 7057, 1007 MB, Amsterdam
Ned Tijdschr Geneeskd 148:2374-8. 2004..However, it is also not possible to conclude definitely that cannabinoids are ineffective; still, this is no basis for official stimulation of their use...- Safety, tolerability, and efficacy of orally administered cannabinoids in MSJ Killestein
Department of Neurology, VU Medical Center, Amsterdam, The Netherlands
Neurology 58:1404-7. 2002..Compared with placebo, neither THC nor plant-extract treatment reduced spasticity. Both THC and plant-extract treatment worsened the participant's global impression... - Glutamate inhibition in MS: the neuroprotective properties of riluzoleJoep Killestein
Department of Neurology, VU Medical Centre, P O Box 7057, 1007 MB, Amsterdam, The Netherlands
J Neurol Sci 233:113-5. 2005..The results indicate an effect on mechanisms involving lesion evolution and axonal loss, but no clear effect on new lesion formation. However, the data suffer from several limitations and must be confirmed in future trials... - Cytokine producing CD8+ T cells are correlated to MRI features of tissue destruction in MSJoep Killestein
Department of Neurology, VU Medical Centre, P O Box 7057, 1007 MB Amsterdam, The Netherlands
J Neuroimmunol 142:141-8. 2003..To our knowledge, this study provides the first direct immunophenotypic evidence of cytokine producing CD8(+) T cells being directly related to long-term development of MRI features of demyelination and axonal loss... - Cannabinoids in multiple sclerosis: urgent need for long term trialsJ Killestein
Department of Neurology, VU Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
J Neurol Neurosurg Psychiatry 76:1612. 2005 - Determinants of interferon ? efficacy in patients with multiple sclerosisJoep Killestein
Department of Neurology MS Center Amsterdam, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
Nat Rev Neurol 7:221-8. 2011.... - Immunomodulatory effects of orally administered cannabinoids in multiple sclerosisJ Killestein
Department of Neurology, VU Medical Center, P O Box 7057, 1007 MB Amsterdam, The Netherlands
J Neuroimmunol 137:140-3. 2003..In the subgroup of patients with high adverse event scores, we found an increase in plasma IL-12p40 (p=0.002). The results suggest pro-inflammatory disease-modifying potential of cannabinoids in MS... - Baseline T cell reactivity in multiple sclerosis is correlated to efficacy of interferon-betaJ Killestein
Department of Neurology, VU Medical Center, P O Box 7057, 1007 MB, Amsterdam, The Netherlands
J Neuroimmunol 133:217-24. 2002..Evidence suggests a role of T cell reactivity in autoimmune diseases. Interferon (IFN)-beta blocks in vitro proliferation of human T cells... - Oral treatment for multiple sclerosisJoep Killestein
Department of Neurology, Multiple Sclerosis Centre Amsterdam, Vrije University Medical Centre, Amsterdam, Netherlands
Lancet Neurol 10:1026-34. 2011.... - Natalizumab drug holiday in multiple sclerosis: poorly toleratedJoep Killestein
Department of Neurology, MS Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
Ann Neurol 68:392-5. 2010.... - Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosisLaura F van der Voort
Department of Neurology, VU Medical Center, De Boelelaan 1117, PO Box 7057, 1007 MB Amsterdam, The Netherlands
Arch Neurol 67:402-7. 2010..To confirm that neutralizing antibodies (NAb) to interferon beta can persist after therapy withdrawal and to evaluate whether persisting NAb are associated with a worse clinical disease course in multiple sclerosis (MS)... - Analysis of multiple candidate genes in association with phenotypes of multiple sclerosisMadeleine H Sombekke
Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
Mult Scler 16:652-9. 2010..These results support our hypothesis that disease severity is determined by clinical variables and genetic influences (through several genes with small effects) in concert... - Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive diseaseJ Killestein
Department of Neurology, VU Medical Center, Amsterdam, The Netherlands
Mult Scler 7:145-50. 2001.... - Expression of adhesion molecules on peripheral lymphocytes predicts future lesion development in MSM Judith Eikelenboom
Department of Neurology, VU University Medical Center, P O Box 7057, Amsterdam 1007, The Netherlands
J Neuroimmunol 158:222-30. 2005..05) and r=0.29; p<0.05, respectively) cells was significantly related to increase in T2 lesion load. Our study provides further evidence for the involvement of integrins in lesion development, shown as T2 lesions on MRI in MS... - Current trials in multiple sclerosis: established evidence and future hopesJoep Killestein
Department of Neurology, MS Centre, VU Medical Centre Amsterdam, Amsterdam, The Netherlands
Curr Opin Neurol 18:253-60. 2005..On the other hand, it is exciting to witness how increased insight in the pathophysiology of the disease and its symptoms has led to a series of new, innovative treatment modalities... - Monocyte activation and disease activity in multiple sclerosis. A longitudinal analysis of serum MRP8/14 levelsSarah Floris
Department of Molecular Cell Biology, VU Medical Center, P.O. Box 7057, 1007 MB, Amsterdam, The Netherlands
J Neuroimmunol 148:172-7. 2004..Therefore, we conclude that although MRP8/14 expression is a good histopathological marker for monocyte activation, serum levels of these proteins do not correlate with disease activity in RR MS... - Interferon beta in multiple sclerosis: predicting response at an early stageJoep Killestein
Department of Neurology, VU Medical Centre Amsterdam, The Netherlands
J Neurol Neurosurg Psychiatry 79:616-7. 2008 - Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosisChris H Polman
Department of Neurology, MS Center Amsterdam, Free University Medical Center, Amsterdam, Netherlands
Lancet Neurol 9:740-50. 2010..In patients who are doing poorly clinically, therapy should be switched irrespective of NAb or MxA bioactivity... - Antibodies against aquaporin-4 in neuromyelitis optica: distinction between recurrent and monophasic patientsImmy A Ketelslegers
Department of Neurology, MS Centre ErasMS, Erasmus University Medical Centre, The Netherlands
Mult Scler 17:1527-30. 2011..AQP4 antibodies were absent in monophasic NMO patients, while samples in recurrent cases remained positive during follow-up. We conclude that the pathogenesis of monophasic NMO may be different from that of relapsing NMO... - Cannabinoids in multiple sclerosis: do they have a therapeutic role?Joep Killestein
Department of Neurology, VU Medical Center, Amsterdam 1007 MB, The Netherlands
Drugs 64:1-11. 2004..Therefore, convincing evidence that cannabinoids are effective in MS is still lacking... - Antibody-mediated suppression of Vbeta5.2/5.3(+) T cells in multiple sclerosis: results from an MRI-monitored phase II clinical trialJoep Killestein
Department of Neurology, VU Medical Center, Amsterdam, The Netherlands
Ann Neurol 51:467-74. 2002..In conclusion, consistent suppression of Vbeta 5.2/5.3(+) T cells was achieved. However, the effect size on magnetic resonance imaging was considerably less than the targeted 60%... - HLA-DRB1*1501 and spinal cord magnetic resonance imaging lesions in multiple sclerosisMadeleine H Sombekke
Department of Neurology, VU University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
Arch Neurol 66:1531-6. 2009..Multiple sclerosis (MS) is a heterogeneous neurologic disease with extensive variation with respect to the most affected central nervous system region (brain vs spinal cord)... - Biomarker research in multiple sclerosis: addressing axonal damage and heterogeneityCharlotte E Teunissen
VU University Medical Center, Department of Molecular Cell Biology and Immunology, MS Center Amsterdam, NeuroUnit Biomarkers for Inflammation and Neurodegneration Amsterdam, FdG, PO Box 7057, 1007 MB, Amsterdam, The Netherlands www bioms eu
Biomark Med 1:111-9. 2007..Such networks enhance the opportunities to obtain sufficient samples for in-depth studies on biomarkers in precious material, such as cerebrospinal fluid... - Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonistB W van Oosten
Department of Neurology, VU University Medical Centre, P O Box 7057, 1007 MB Amsterdam, The Netherlands
Mult Scler 10:330-1. 2004..The occurrence of MS several months after starting a cannabinoid receptor antagonist suggests that the cannabinoid system might indeed be relevant to disease pathogenesis in MS... - Cerebrospinal fluid anti-myelin antibodies are related to magnetic resonance measures of disease activity in multiple sclerosisM H J Vogt
Department of Molecular Cell Biology and Immunology, VU University Medical Centre, Amsterdam, The Netherlands
J Neurol Neurosurg Psychiatry 80:1110-5. 2009..Here, myelin particles were used to detect anti-myelin antibodies in the CSF of MS patients. Subsequently, their relation with MRI parameters was evaluated... - Lack of interferon-beta bioactivity is associated with the occurrence of relapses in multiple sclerosisL F van der Voort
Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
Eur J Neurol 16:1049-52. 2009..Although absent IFNbeta bioactivity is associated with NAb and NAb are associated with reduced drug efficacy, the direct relationship between IFNbeta bioactivity and clinical disease activity is largely unknown... - Active MRI lesion appearance in MS patients is preceded by fluctuations in circulating T-helper 1 and 2 cellsJ Killestein
Department of Immunobiology, CLB and Laboratory of Experimental and Clinical Immunology of the University of Amsterdam, Amsterdam, The Netherlands
J Neuroimmunol 118:286-94. 2001..However, the exact mechanisms by which T cells and cytokines contribute to disease activity remain to be clarified... - Gender differences in multiple sclerosis: cytokines and vitamin DM J Eikelenboom
Department of Neurology, VU University Medical Center, 1007MB Amsterdam, The Netherlands
J Neurol Sci 286:40-2. 2009..The immune system is influenced by different factors including hormones and seasonal fluctuations (vitamin D). This overview will highlight the gender differences in MS, with emphasis on the cytokines and vitamin D... - TNFalpha production by CD4(+) T cells predicts long-term increase in lesion load on MRI in MSJ Killestein
Department of Neurology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
Neurology 57:1129-31. 2001..A correlation was found between the percentage of tumor necrosis factor-alpha-producing CD4(+) T cells at baseline and the change in T2 lesion load during 3-year follow-up (r = 0.79, adjusted r(2) = 0.59, p = 0.001)... - Serum homocysteine levels in relation to clinical progression in multiple sclerosisC E Teunissen
Molecular Cell Biology and Immunology, VU University Medical Centre, FdG, PO Box 7057, 1007 MB Amsterdam, The Netherlands
J Neurol Neurosurg Psychiatry 79:1349-53. 2008..Homocysteine levels may be elevated in patients with multiple sclerosis (MS) but large studies are lacking and the relation with disease progression remains to be determined... - Chemokine receptor expression on T cells is related to new lesion development in multiple sclerosisM J Eikelenboom
Department of Neurology, VU Medical Centre, De Boelelaan 1117, PO Box 7057, 1007 MB, Amsterdam, The Netherlands
J Neuroimmunol 133:225-32. 2002..Our results suggest that chemokines may play a more important role in the development of new lesions in MS than in the long-term outcome of those lesions... - Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MSL F van der Voort
VU Medical Center, Department of Neurology, De Boelelaan 1117, PO Box 7057, 1007 MB Amsterdam, The Netherlands
Neurology 75:1228-33. 2010..To determine if myxovirus resistance protein A (MxA) mRNA is related to clinical disease activity in multiple sclerosis (MS)... - Sex differences in proinflammatory cytokine profiles of progressive patients in multiple sclerosisM J Eikelenboom
Department of Neurology at the VU Medical Centre, De Boelelaan 1117, 1007 MB Amsterdam, The Netherlands
Mult Scler 11:520-3. 2005..In conclusion, the data presented indicate that cytokine production and sex differences in cytokine production might differ between disease phases, probably related to underlying disease mechanisms... - Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practiceL F van der Voort
Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
Mult Scler 15:212-8. 2009..Unclear is how to apply IFN beta bioactivity measurements (quantification of Myxovirus resistance protein A (MxA) mRNA) in clinical practice... - Quantification of amyloid-beta 40 in cerebrospinal fluidNicolaas A Verwey
Department of Neurology, VU University Medical Center, Alzheimer Center Amsterdam, P O Box 7057, 1007 MB Amsterdam, The Netherlands
J Immunol Methods 348:57-66. 2009..Reliable methods to detect these biomarkers in CSF are of great importance for understanding the disease mechanisms and for diagnostic purposes... - Statins for the treatment of multiple sclerosis: cautious hopeChris H Polman
VU Medical Centre Amsterdam, 1007 MB Amsterdam, Netherlands
Lancet 363:1570. 2004 - Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patientsLisa G M van Baarsen
Department of Molecular Cell Biology and Immunology, VU Medical Center, Amsterdam, The Netherlands
PLoS ONE 3:e1927. 2008..Multiple sclerosis (MS) is a heterogeneous disease. In order to understand the partial responsiveness to IFNbeta in Relapsing Remitting MS (RRMS) we studied the pharmacological effects of IFNbeta therapy... - T lymphocytes impair P-glycoprotein function during neuroinflammationGijs Kooij
Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, The Netherlands
J Autoimmun 34:416-25. 2010..Loss of vascular P-gp function during neuroinflammation may disturb brain homeostasis and thereby aggravate disease progression via exposure of vulnerable CNS cells to detrimental compounds... - The physiological variation of the retinal nerve fiber layer thickness and macular volume in humans as assessed by spectral domain-optical coherence tomographyLisanne J Balk
Department of Neurology, MS Center, VU University Medical Center, De Boelelaan 1118, 1081 HZ Amsterdam, The Netherlands
Invest Ophthalmol Vis Sci 53:1251-7. 2012..The aim of this study was to determine whether there is a physiological quantifiable degree of variation of these structures in humans... - Differential effect of drug interference in immunogenicity assaysMargreet H Hart
Department of Immunopathology, Sanquin Research and Landsteiner Laboratory AMC, Amsterdam, The Netherlands
J Immunol Methods 372:196-203. 2011..In summary, we showed that a bridging elisa is susceptible to drug interference and typically measures ADA only in absence of detectable drug levels... - Seasonal variation in immune measurements and MRI markers of disease activity in MSJ Killestein
Department of Neurology, VU Medical Center, Amsterdam, The Netherlands
Neurology 58:1077-80. 2002..Recently, the results of cross-sectional studies suggested seasonal variation of both interferon (IFN)-gamma production and the number of active MRI lesions in MS... - No evidence of misdiagnosis in patients with multiple sclerosis and repeated positive anticardiolipin antibody testing based on magnetic resonance imaging and long term follow-upM Liedorp
Department of Neurology, MS Centre Amsterdam, Vrije Universiteit Medical Centre, PO Box 7057, 1007 MB, Amsterdam, The Netherlands
J Neurol Neurosurg Psychiatry 78:1146-8. 2007..Also, to determine if these patients form a separate subgroup in terms of long term follow-up and MRI characteristics... - MS functional composite: relation to disease phenotype and disability strataN F Kalkers
Department of Neurology, Academisch Ziekenhuis Vrije Universiteit Amsterdam, The Netherlands
Neurology 54:1233-9. 2000.... - Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in womenJj Kragt
Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
Mult Scler 15:9-15. 2009..The geographical distribution of MS is striking with a prevalence that increases with latitude. For this reason, vitamin D deficiency is considered a possible pathogenic co-factor in MS... - Neutralizing antibodies to interferon-beta may persist after cessation of therapy: what impact could they have?Chris Polman
Mult Scler 12:245-6. 2006 - Cannabis use in multiple sclerosis: excited interestJoep Killestein
Can J Neurol Sci 30:181-2. 2003 - Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosisRachel Farrell
J Int Med Res 36:204-8; author reply 208-10. 2008 - The therapeutic value of cannabinoids in MS: real or imaginary?Joep Killestein
Mult Scler 10:339-40. 2004 - Cannabinoids and immune functionJoep Killestein
JAMA 290:754; author reply 755. 2003 - ASCOT-LLA: questions about the benefits of atorvastatinJoep Killestein
Lancet 361:1986; author reply 1986-7. 2003 - Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitusJoep Killestein
N Engl J Med 347:1116-7; author reply 1116-7. 2002 - Neutralising antibodies to interferon beta in multiple sclerosis : expert panel reportHans P Hartung
Dept of Neurology, Heinrich Heine University, Moorenstrasse 5, 40225, Dusseldorf, Germany
J Neurol 254:827-37. 2007....